WEE1 and non-small cell lung carcinoma: In this study, we find that WEE1 polymorphism is strongly associated with the treatment efficacy of DNA-damaging agents in patients with advanced NSCLC and can be used as a valuable biomarker for predictions of efficacy followed by a platinum-gemcitabine regimen.